Skip to main content

Biospecimen Collection (NCT07158021)

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial: a one-minute explainerNCT071580211 min

Biospecimen Collection trial for Anatomic Stage I Breast Cancer AJCC v8 (NCT07158021). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for pre- or peri-menopausal adult women taking oral endocrine therapy for stage one through three or metastatic breast cancer. Chemotherapy must be complete.

The idea: leuprolide and goserelin suppress ovarian estrogen production, which can fuel breast cancer. Three nonrandomized groups receive leuprolide, 3.75 or 7.5 milligrams into muscle, or goserelin, 3.6 milligrams under the skin, every four weeks for up to twenty-four weeks. Blood tests measure estrogen suppression; questionnaires assess symptoms.

This phase 2 study plans 75 patients. Norah Henry leads at Michigan, Ann Arbor, the sole recruiting US site.

Public record; not medical advice.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.